18 recruiting, 14 not yet recruiting, 1 completed, 1 unknown. 16 Phase 2, 9 Phase 1, 7 Not applicable, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Not yet recruiting 9, Recruiting 7 |
| Phase 1 | 9 | Not yet recruiting 5, Recruiting 4 |
| Not applicable | 7 | Recruiting 5, Not yet recruiting 2 |
| Early Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Soft Tissue Sarcoma (STS): new trials by email Literature Review of Soft Tissue Sarcoma (STS) trials Research Report on Soft Tissue Sarcoma (STS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma UTD2 + tislelizumab + doxorubicin - Soft Tissue Sarcoma (STS), Utidelone | Phase 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals Co., Ltd. | 49 | 2026-10-18 | 2026-09-25 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma Lifileucel - Sarcoma, Soft Tissue Sarcoma (STS) | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 80 | 2026-10-02 | 2026-10-09 |
| A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma SOT106 - Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS) | Phase 1 / Phase 2 | Not yet recruiting | SOTIO Biotech a.s. | 70 | 2026-09-30 | 2026-09-03 |
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers AL58805, AL8326, Eribulin - Endometrial Neoplasms, Soft Tissue Sarcoma (STS) | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma 5-ALA - Soft Tissue Sarcoma (STS) | Early Phase 1 | Not yet recruiting | University of Colorado, Denver | 20 | 2026-09-01 | 2026-07-22 |
| A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma. bexmarilimab, Doxorubicin - Soft Tissue Sarcoma (STS) | Phase 1 / Phase 2 | Recruiting | MedSIR | 278 | 2026-08-20 | 2026-08-31 |
| Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention Exercise Triage and Personalized Exercise Program - Sarcoma, Bone Sarcoma | Not applicable | Recruiting | Dana-Farber Cancer Institute | 40 | 2026-08-01 | 2026-08-26 |
| OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) OVV-01，AK112 - Soft Tissue Sarcoma (STS) | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2026-08-01 | 2026-06-16 |
| "Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache)" Individualized Exercise Program - Bone Sarcoma, Soft Tissue Sarcoma (STS) | Not applicable | Not yet recruiting | Universität Duisburg-Essen | 46 | 2026-08-01 | 2026-07-27 |
| Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma Anlotinib, Penpulimab, Preoperative Radiotherapy - Soft Tissue Sarcoma (STS) | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 274 | 2026-07-01 | 2026-05-28 |
| Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors 68Ga-DFC413, 68Ga-NNS309 - Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Novartis Pharmaceuticals | 66 | 2026-06-23 | 2026-08-27 |
| Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02) ultra-hypofractionated radiotherapy combined with immunotherapy - Soft Tissue Sarcoma (STS), Retroperitoneal Sarcoma | Not applicable | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 28 | 2026-02-12 | 2026-02-12 |
| A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma Spatially Fractionated Radiation Therapy Combined with Toripalimab and Human Granulocyte-Macrophage Colony-Stimulating Factor for Injection - Soft Tissue Sarcoma (STS) | Phase 2 | Not yet recruiting | First Affiliated Hospital of Guangxi Medical University | 25 | 2026-02-01 | 2026-01-15 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Sarcoma Care Adherence and Survival in Strasbourg Soft Tissue Sarcoma (STS) | Recruiting | University Hospital, Strasbourg, France | 900 | 2025-11-27 | 2026-10-08 | |
| A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma. QL1706 + Eribulin + Anlotinib + Radiotherapy - Soft Tissue Sarcoma (STS) | Phase 2 | Not yet recruiting | Fudan University | 46 | 2025-10-01 | 2025-10-03 |
| Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes: - Urothelial Carcinoma, Renal Cancer | Not applicable | Recruiting | Institut Claudius Regaud | 450 | 2025-07-23 | 2026-06-15 |
| EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma Lymphodepletion, TCR-T cells (MDG1015) - Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer | Phase 1 | Not yet recruiting | Medigene AG | 55 | 2025-07-01 | 2024-12-27 |
| Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma Spatially Fractionated Radiotherapy, Conventional Radiotherapy - Soft Tissue Sarcoma (STS) | Not applicable | Recruiting | Shandong Cancer Hospital and Institute | 106 | 2025-05-20 | 2026-10-13 |
Showing 20 of 34. Sign in to see all of them.
Sarcoma (34) · Osteosarcoma (5) · Liposarcoma (4) · Bone Neoplasms (2) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Glioblastoma (2) · Histiocytoma, Malignant Fibrous (2) · Leiomyosarcoma (2) · Melanoma (2) · Neoplasms (2) · Sarcoma, Synovial (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1)
Neoplasms by Histologic Type (34) · Neoplasms, Connective and Soft Tissue (34) · Neoplasms (32) · Neoplasms by Site (9) · Neoplasms, Connective Tissue (8) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Neoplasms, Adipose Tissue (5) · Neoplasms, Bone Tissue (5) · Neoplasms, Glandular and Epithelial (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Carcinoma (4)
anlotinib (4) · Doxorubicin (3) · eribulin (3) · Aminolevulinic Acid (1) · Bevacizumab (1) · Bronchoscopy (1) · Epirubicin (1) · Fulvestrant (1) · Immunotherapy (1) · Injections (1) · Lomustine (1) · Metastasectomy (1) · Neoadjuvant Therapy (1) · Paclitaxel (1) · Radiotherapy (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Sun Yat-sen University (3) · Advenchen Pharmaceuticals, LLC. (2) · Fudan University (2) · Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas (1) · Beijing Biostar Pharmaceuticals Co., Ltd. (1) · Dana-Farber Cancer Institute (1) · European Georges Pompidou Hospital (1) · First Affiliated Hospital of Guangxi Medical University (1) · GI Innovation, Inc. (1) · Hadassah Medical Organization (1) · Hansoh BioMedical R&D Company (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Institut Claudius Regaud (1) · Iovance Biotherapeutics, Inc. (1)
China (9) · United States (7) · France (3) · Spain (2) · Canada (1) · Denmark (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Moldova (1) · Netherlands (1) · Norway (1) · South Korea (1) · United Kingdom (1)
Judy Chen (2) · Carlos K Matsuoka, MD (1) · Chao Cao, MD (1) · David Dr. Zhen, MD (1) · Gooitzen van Dam, MD, PhD (1) · Ina Elisa Kirchberg, Dr. med. (1) · Ivar Hompland, MD, PhD (1) · Jeffrey A How, MD (1) · Jinbo Yue, Doctor (1) · Kjetil Boye, MD, PhD (1) · Laurent Lantieri, MD (1)
PMID 16648043, PMID 26885645, PMID 30173528, PMID 30659522, PMID 32138774, PMID 34624862, PMID 35033148, PMID 36656388, PMID 42022357
2025 (2)